Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Therapeutic management options for stage III non-small cell lung cancer.

Yoon SM, Shaikh T, Hallman M.

World J Clin Oncol. 2017 Feb 10;8(1):1-20. doi: 10.5306/wjco.v8.i1.1. Review.

2.

The use of dose-escalated radiation for locally advanced non-small cell lung cancer in the U.S., 2004-2013.

Christodouleas JP, Hall MD, van der Pas MA, Guo W, Schultheiss TE, Gabriel P.

Radiat Oncol. 2017 Jan 17;12(1):19. doi: 10.1186/s13014-016-0755-y.

3.

Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance).

Schild SE, Hillman SL, Tan AD, Ross HJ, McGinnis WL, Garces YA, Graham DL, Adjei AA, Jett JR; Mayo Clinic, North Central Cancer Treatment Group..

J Thorac Oncol. 2017 Apr;12(4):697-703. doi: 10.1016/j.jtho.2016.12.021. Epub 2017 Jan 12.

PMID:
28089762
4.

Dose escalation for unresectable locally advanced non-small cell lung cancer: end of the line?

Hong JC, Salama JK.

Transl Lung Cancer Res. 2016 Feb;5(1):126-33. doi: 10.3978/j.issn.2218-6751.2016.01.07.

5.

Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer.

Nguyen QN, Ly NB, Komaki R, Levy LB, Gomez DR, Chang JY, Allen PK, Mehran RJ, Lu C, Gillin M, Liao Z, Cox JD.

Radiother Oncol. 2015 Jun;115(3):367-72. doi: 10.1016/j.radonc.2015.05.014. Epub 2015 May 28.

6.

Combined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study.

Sachpekidis C, Thieke C, Askoxylakis V, Nicolay NH, Huber PE, Thomas M, Dimitrakopoulou G, Debus J, Haberkorn U, Dimitrakopoulou-Strauss A.

Am J Nucl Med Mol Imaging. 2015 Jan 15;5(2):127-42. eCollection 2015 Jan 15.

7.

Definitive radiotherapy in locally advanced non-small cell lung cancer: dose and fractionation.

Dağoğlu N, Karaman Ş, Arifoğlu A, Küçücük S, Oral EN.

Balkan Med J. 2014 Dec;31(4):278-85. doi: 10.5152/balkanmedj.2014.14496. Epub 2014 Dec 1. Review.

8.

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.

Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H.

Lancet Oncol. 2015 Feb;16(2):187-99. doi: 10.1016/S1470-2045(14)71207-0. Epub 2015 Jan 16.

9.

Radiation dose effect in locally advanced non-small cell lung cancer.

Kong FM, Zhao J, Wang J, Faivre-Finn C.

J Thorac Dis. 2014 Apr;6(4):336-47. doi: 10.3978/j.issn.2072-1439.2014.01.23. Review.

10.

Accuracy of deformable image registration for contour propagation in adaptive lung radiotherapy.

Hardcastle N, van Elmpt W, De Ruysscher D, Bzdusek K, Tomé WA.

Radiat Oncol. 2013 Oct 18;8:243. doi: 10.1186/1748-717X-8-243.

11.
12.
13.

Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer.

Karam SD, Horne ZD, Hong RL, McRae D, Duhamel D, Nasr NM.

Radiat Oncol. 2013 Jul 10;8:179. doi: 10.1186/1748-717X-8-179.

14.

Human apurinic/apyrimidinic endonuclease siRNA inhibits the angiogenesis induced by X-ray irradiation in lung cancer cells.

Gu X, Cun Y, Li M, Qing Y, Jin F, Zhong Z, Dai N, Qian C, Sui J, Wang D.

Int J Med Sci. 2013 May 20;10(7):870-82. doi: 10.7150/ijms.5727. Print 2013.

15.

Dosimetric Feasibility of Dose Escalation Using SBRT Boost for Stage III Non-Small Cell Lung Cancer.

Hepel JT, Peter J, Hiatt JR, Patel S, Osibanjo O, Safran H, Curran B, Dipetrillo T.

Front Oncol. 2012 Sep 26;2:124. doi: 10.3389/fonc.2012.00124. eCollection 2012 Sep 26.

16.

A modified Phase I trial of radiation dose escalation in 3D conformal radiation therapy with concurrent vinorelbine and carboplatin chemotherapy for non-small-cell lung cancer.

Lin Q, Liu Y, Wang N, Huang Y, Ge X, Ren X, Chen X, Hu J, Guo Z, Zhao Y, Asaumi J.

J Radiat Res. 2013 Jan;54(1):126-34. doi: 10.1093/jrr/rrs081. Epub 2012 Sep 17.

17.

Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-modulated radiation therapy, or proton beam therapy for non-small cell lung cancer.

Gomez DR, Tucker SL, Martel MK, Mohan R, Balter PA, Lopez Guerra JL, Liu H, Komaki R, Cox JD, Liao Z.

Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):1010-6. doi: 10.1016/j.ijrobp.2012.01.071. Epub 2012 Aug 21.

18.

High-dose 3-dimensional conformal radiotherapy with concomitant vinorelbine plus carboplatin in patients with non-small cell lung cancer: A feasibility study.

Lin Q, Wang J, Liu Y, Su H, Wang N, Huang Y, Liu CX, Zhang P, Zhao Y, Chen K.

Oncol Lett. 2011 Jul;2(4):669-674. Epub 2011 May 16.

19.

Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis.

Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, Bradley JD, Kim TH, Ramella S, Marks LB, De Petris L, Stitt L, Rodrigues G.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):444-50. doi: 10.1016/j.ijrobp.2012.04.043. Epub 2012 Jun 9. Review.

20.

Radiation Dose Escalation in Stage III Non-Small-Cell Lung Cancer.

Terakedis B, Sause W.

Front Oncol. 2011 Nov 30;1:47. doi: 10.3389/fonc.2011.00047. eCollection 2011 Nov 30.

Supplemental Content

Support Center